Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/143223
Full metadata record
DC FieldValueLanguage
dc.creatorFragão-Marques, M
dc.creatorMiranda, I
dc.creatorMartins, D
dc.creatorBarroso, I
dc.creatorMendes, C
dc.creatorPereira-Neves, A
dc.creatorFalcão-Pires, I
dc.creatorLeite-Moreira, A
dc.date.accessioned2022-08-23T14:45:48Z-
dc.date.available2022-08-23T14:45:48Z-
dc.date.issued2020
dc.identifier.issn1471-2261
dc.identifier.urihttps://hdl.handle.net/10216/143223-
dc.description.abstractBackground. This study aimed to evaluate atrium extracellular matrix remodeling in atrial fibrillation (AF) patients with severe aortic stenosis, through histological fibrosis quantification and extracellular matrix gene expression analysis, as well as serum quantification of selected protein targets. Methods. A posthoc analysis of a prospective study was performed in a cohort of aortic stenosis patients. Between 2014 and 2019, 56 patients with severe aortic stenosis submitted to aortic valve replacement surgery in a tertiary hospital were selected. Results. Fibrosis was significantly increased in the AF group when compared to sinus rhythm (SR) patients (p = 0.024). Moreover, cardiomyocyte area was significantly higher in AF patients versus SR patients (p = 0.008). Conversely, collagen III gene expression was increased in AF patients (p = 0.038). TIMP1 was less expressed in the atria of AF patients. MMP16/TIMP4 ratio was significantly decreased in AF patients (p = 0.006). TIMP1 (p = 0.004) and TIMP2 (p = 0.012) were significantly increased in the serum of AF patients. Aortic valve maximum (p = 0.0159) and mean (p = 0.031) gradients demonstrated a negative association with serum TIMP1. Conclusions. Atrial fibrillation patients with severe aortic stenosis present increased atrial fibrosis and collagen type III synthesis, with extracellular matrix remodelling demonstrated by a decrease in the MMP16/TIMP4 ratio, along with an increased serum TIMP1 and TIMP2 proteins.
dc.description.sponsorshipThis study was supported by the Cardiovascular R&D Center, financed by national funds through FCT—Fundação para a Ciência e Tecnologia, I.P., under the scope of the projects UID/IC/00051/2019 and UIDP/00051/2020, and Fundo Europeu de Desenvolvimento Regional (FEDER) through Compete 2020 – Programa Operacional Competitividade E Internacionalização (POCI), the project DOCNET (Norte-01-0145-FEDER-000003), supported by Norte Portugal regional operational programme (Norte 2020), under the Portugal 2020 partnership agreement, through the European Regional Development Fund (ERDF), the project NETDIAMOND (POCI-01-0145-FEDER-016385), supported by European Structural And Investment Funds, Lisbon’s regional operational program 2020.
dc.language.isoeng
dc.publisherBMC
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID/IC/00051/2019/PT
dc.relationinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP/00051/2020/PT
dc.relation.ispartofBMC Cardiovasc Disord. 2020 Oct 31;20(1):468
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAtrial fibrillation
dc.subjectAortic stenosis
dc.subjectFibrosis
dc.subjectAtrial remodeling
dc.subjectBiomarkers
dc.titleAtrial matrix remodeling in atrial fibrillation patients with aortic stenosis
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Saúde Pública da Universidade do Porto
dc.identifier.doi10.1186/s12872-020-01754-0
dc.relation.publisherversionhttps://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-020-01754-0
Appears in Collections:ISPUP - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
fragao-marques-bmccd-2020.pdf1.94 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons